These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 14639580

  • 1. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies.
    Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF.
    Muscle Nerve; 2003 Dec; 28(6):659-82. PubMed ID: 14639580
    [Abstract] [Full Text] [Related]

  • 2. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
    Figarella-Branger D, Schleinitz N, Boutière-Albanèse B, Camoin L, Bardin N, Guis S, Pouget J, Cognet C, Pellissier JF, Dignat-George F.
    J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
    [Abstract] [Full Text] [Related]

  • 3. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses.
    De Paepe B, Creus KK, De Bleecker JL.
    Ann N Y Acad Sci; 2007 Aug; 1109():441-53. PubMed ID: 17785333
    [Abstract] [Full Text] [Related]

  • 4. Cellular mechanisms in inflammatory myopathies.
    Hohlfeld R, Goebels N, Engel AG.
    Baillieres Clin Neurol; 1993 Nov; 2(3):617-35. PubMed ID: 8156145
    [Abstract] [Full Text] [Related]

  • 5. Update on idiopathic inflammatory myopathies.
    Briani C, Doria A, Sarzi-Puttini P, Dalakas MC.
    Autoimmunity; 2006 May; 39(3):161-70. PubMed ID: 16769649
    [Abstract] [Full Text] [Related]

  • 6. Role of cytokines and chemokines in idiopathic inflammatory myopathies.
    De Paepe B, Creus KK, De Bleecker JL.
    Curr Opin Rheumatol; 2009 Nov; 21(6):610-6. PubMed ID: 19726994
    [Abstract] [Full Text] [Related]

  • 7. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
    Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC.
    Neurobiol Dis; 2007 Mar; 25(3):665-74. PubMed ID: 17207628
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic approaches in patients with inflammatory myopathies.
    Dalakas MC.
    Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
    [Abstract] [Full Text] [Related]

  • 9. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.
    Lundberg I, Kratz AK, Alexanderson H, Patarroyo M.
    Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873
    [Abstract] [Full Text] [Related]

  • 10. Chemokines and dendritic cells in inflammatory myopathies.
    Tournadre A, Miossec P.
    Ann Rheum Dis; 2009 Mar; 68(3):300-4. PubMed ID: 19213746
    [Abstract] [Full Text] [Related]

  • 11. Potential therapeutic targets for idiopathic inflammatory myopathies.
    De Bleecker JL, Creus KK, De Paepe B.
    Drug News Perspect; 2006 Nov; 19(9):549-57. PubMed ID: 17220960
    [Abstract] [Full Text] [Related]

  • 12. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
    Raju R, Dalakas MC.
    Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
    [Abstract] [Full Text] [Related]

  • 13. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjörnsson M, Lindvall B, Lundberg IE.
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [Abstract] [Full Text] [Related]

  • 14. Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies.
    Schleinitz N, Cognet C, Guia S, Laugier-Anfossi F, Baratin M, Pouget J, Pelissier JF, Harle JR, Vivier E, Figarella-Branger D.
    Arthritis Rheum; 2008 Oct; 58(10):3216-23. PubMed ID: 18821690
    [Abstract] [Full Text] [Related]

  • 15. Inflammatory muscle diseases: a critical review on pathogenesis and therapies.
    Dalakas MC.
    Curr Opin Pharmacol; 2010 Jun; 10(3):346-52. PubMed ID: 20409756
    [Abstract] [Full Text] [Related]

  • 16. Immune effector mechanisms in inflammatory myopathies.
    Engel AG, Arahata K, Emslie-Smith A.
    Res Publ Assoc Res Nerv Ment Dis; 1990 Jun; 68():141-57. PubMed ID: 2158132
    [Abstract] [Full Text] [Related]

  • 17. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis.
    Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S, Marie SK.
    Autoimmun Rev; 2006 Feb; 5(2):93-100. PubMed ID: 16431335
    [Abstract] [Full Text] [Related]

  • 18. Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects.
    Dalakas MC.
    Rev Neurol (Paris); 2002 Oct; 158(10 Pt 1):948-58. PubMed ID: 12407303
    [Abstract] [Full Text] [Related]

  • 19. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy.
    Haslbeck KM, Friess U, Schleicher ED, Bierhaus A, Nawroth PP, Kirchner A, Pauli E, Neundörfer B, Heuss D.
    Acta Neuropathol; 2005 Sep; 110(3):247-54. PubMed ID: 15986224
    [Abstract] [Full Text] [Related]

  • 20. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies.
    Lundberg IE.
    Curr Rheumatol Rep; 2000 Jun; 2(3):216-24. PubMed ID: 11123062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.